journal article·2004-08

Radionuclides-hyaluronan-conjugate thromboresistant coatings to prevent in-stent restenosis

Benjamin Thierry, Françoise M Winnik, Yahye Merhi, Jim Silver, Maryam Tabrizian

Biomaterials· Volume 25· Issue 17
Publisher page

Abstract

Catheter-based brachytherapy is one of the most effective modalities to inhibit hyperplasia following revascularization procedures. Radioactive stents have failed, however, to prevent clinical hyperplasia due to excessive late lumen loss on the edge of the devices. Numerous strategies have been proposed to circumvent the drawbacks of irradiation therapies, such as the use of more appropriate radionuclides or the "hot-end" stents approach. This paper describes versatile radioactive devices obtained by coating plasma functionalized surfaces-stents or catheters-with a hyaluronan (HA)-diethylenetriamine pentaacetic acid (DTPA) conjugate (HA-DTPA) complexed with a gamma or beta radionuclide. Yttrium and indium were used as radionuclide models, due to their suitability for endovascular radiotherapy. X-ray photoelectron microscopy and time-of-flight secondary ions mass spectrometry analyses confirmed the successful immobilization of the HA-DTPA conjugate on both the metallic (NiTi) and polymeric (Teflon) plasma functionalized surfaces. HA-DTPA-coated surfaces were significantly more hydrophilic than bare surfaces (39.5 degrees vs. 67 degrees on NiTi substrate and 29 degrees vs. 128 degrees on Teflon substrate). Therapeutic doses of yttrium and indium were easily loaded onto the surfaces and remained stable over 2 weeks with a radionuclide loss of about 6%. The HA-DTPA-coated Teflon surfaces presented significantly less fibrinogen adsorption than uncoated materials in an in vitro flow model. This approach, which combines the hemocompatibility of HA-coated surfaces and the anti-proliferative effects of an appropriate radiotherapy, constitutes a promising methodology to alleviate the restenosis induced by existing devices.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Coronary Interventions and Diagnostics · Vascular Procedures and Complications · Cerebrovascular and Carotid Artery Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (44)

Show source-provided references
1. Role of stenting in coronary revascularisation
2. Prevention of in-stent restenosis
3. Coronary restenosis elimination with a sirolimus eluting stent10.1053/euhj.2001.2892 ↗
4. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis10.1161/01.CIR.103.18.2289 ↗
5. American Heart Association 2001 scientific sessions10.1161/hc4601.102698 ↗
6. Sustained suppression of neointimal proliferation by sirolimus-eluting stents10.1161/hc4201.098056 ↗
8. Thin polymer layers formed by polyelectrolyte multilayer techniques on biological surfaces10.1021/la9815749 ↗
9. Use of localised intracoronary beta radiation in treatment of in-stent restenosis10.1016/S0140-6736(02)07741-3 ↗
10. Role of intracoronary brachytherapy for in-stent restenosis?10.1016/S0140-6736(02)07720-6 ↗
11. FDA approval of coronary-artery brachytherapy10.1056/NEJM200101253440410 ↗
12. Late acute thrombosis after coronary brachytherapy
13. How to fix the edge effect of catheter-based radiation therapy in stented arteries10.1161/01.CIR.0000033820.68791.3D ↗
14. The cytotoxicity of corrosion products of nitinol stent wire on cultured smooth muscle cells10.1002/1097-4636(200011)52:2<395::AID-JBM21>3.0.CO;2-B ↗
15. Coronary in-stent restenosis10.1016/S0735-1097(01)01742-9 ↗
16. Histopathologic alterations after endovascular radiation and antiproliferative stents10.1007/s00059-002-2341-3 ↗
17. Physical and chemical limitations to preparation of beta radioactive stents by direct neutron activation10.1016/S0142-9612(02)00355-1 ↗
18. I like the candy, I hate the wrapper10.1161/01.CIR.101.1.3 ↗
19. European high-activity (32)P radioactive stent experience
20. Abatangelo · 2000
21. Reduced thrombus formation by hyaluronic acid coating of endovascular devices10.1161/01.ATV.20.4.1168 ↗
22. Non-fouling properties of polysaccharide-coated surfaces10.1163/156856299X00711 ↗
23. 188Re-ethylene dicysteine10.1097/00006231-200010000-00008 ↗
24. Rhenium-188-labeled DTPA10.1016/S0969-8051(99)00074-8 ↗
25. Quantitative assays of the amount of diethylenetriaminepentaacetic acid conjugated to water-soluble polymers using isothermal titration calorimetry and colorimetry10.1021/bc000109w ↗
26. ASTM F86. Standard practice for surface preparation and marking of metallic surgical implants. Annual Book of ASTM standards, Medical Devices and Services, vol. 13.01, American Society for Testing and Materials, 1995. p. 6–8.
27. Method of immobilization of carboxymethyl-dextran affects resistance to tissue and cell colonization10.1016/S0927-7765(99)00149-6 ↗
28. Nitinol versus stainless steel stents10.1016/S0142-9612(02)00030-3 ↗
29. Gouin S, Valencia Grayeb MV, Winnik FM. Gadolinium diethylenetriamine pentaacetic acid/hyaluronan conjugates: preparation, properties and applications. In: Guiseppi-Elie A, Levon K, editors. Macromolecule–Metal Complexes, Macromolecular Symposia 186. Weinheim, Germany: Wiley-VCH; 2002. p. 105–10.10.1002/1521-3900(200208)186:1<105::AID-MASY105>3.0.CO;2-2 ↗
30. Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media10.1021/bc00031a015 ↗
31. Investigation of organic coatings and coating defects with the help of time-of-flight-secondary ion mass spectrometry (TOF-SIMS)10.1016/S0300-9440(99)00035-1 ↗
32. Synthesis, structure and surface dynamics of phosphorycholine functional biomimicking polymers10.1016/S0142-9612(97)00197-X ↗
33. TOF-SIMS characterization and imaging of controlled-release drug delivery systems10.1021/ac000450+ ↗
34. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group10.1056/NEJM200101253440401 ↗
35. Beta-particle-emitting radioactive stent implantation
36. Prophylaxis of restenosis with (186)Re-labeled stents in a rabbit model10.1161/hc3001.091457 ↗
37. Endovascular irradiation from beta-particle-emitting gold stents results in increased neointima formation in a porcine restenosis model10.1161/01.CIR.101.16.1970 ↗
38. The dosimetry for a coronary artery stent coated with radioactive 188Re and 32P10.1088/0031-9155/45/12/310 ↗
39. Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates10.1021/jm980152t ↗
40. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti- carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies
41. Dosimetry in radionuclide therapies with 90Y-conjugates
42. Evaluation of the serum stability and in vivo biodistribution of CHX- DTPA and other ligands for yttrium labeling of monoclonal antibodies
43. On the molecular basis of fouling resistance10.1163/156856200743869 ↗
44. Short- and intermediate-term results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease10.1161/01.CIR.101.1.18 ↗